New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2013
14:46 EDTMYGNMyriad Genetics test significantly predicts response to cisplatin treatment
Myriad Genetics presented clinical data at the 2013 San Antonio Breast Cancer Symposium that showed the Myriad's HRD, homologous recombination deficiency, test was significantly associated with cisplatin response in patients with triple negative breast cancer. This is the second research study to show that Myriad's HRD test predicts drug response to platinum therapy in triple-negative breast cancer patients. In a prior study, 70 percent of patients with an HRD score =10 responded to the carboplatin-based treatment, compared to only 20 percent of patients with an HRD score < 10. Using the HRD test instead of BRCA status identified more than three times as many patients as likely responders. Myriad has announced two commercial collaborations to further develop the HRD test. In March, the Company announced it is conducting HRD testing on patients enrolled in PharmaMar's Phase 2 study of PM1183. In Nov. 2013, Myriad announced a collaboration with BioMarin that will use the HRD test to identify tumor types that may be sensitive to BioMarin's investigational product candidate, BMN-673. The Company also has two other undisclosed collaborations to evaluate HRD as a companion diagnostic..
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
16:34 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
11:09 EDTMYGNMyriad Genetics advises prior BRACAnalysis news release be disregarded
Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.
10:16 EDTMYGNMyriad Genetics has a conference call hosted by JPMorgan
Subscribe for More Information
05:48 EDTMYGNMyriad Genetics submits premarket approval to FDA for BRACAnalysis
Subscribe for More Information
April 4, 2014
11:07 EDTMYGNMyriad Genetics price target raised to $42 from $34 at Piper Jaffray
Piper Jaffray raised its price target for Myriad Genetics shares to $42 to reflect CMS' recent decision to increase BRCA reimbursement. The firm keeps an Overweight rating on the stock.
10:02 EDTMYGNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:48 EDTMYGNMyriad Genetics upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
06:46 EDTMYGNMyriad Genetics upgraded to Buy from Neutral at Mizuho
April 3, 2014
07:37 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho raised Myriad's price target to $40 from $28 following the better than expected CMS pricing for BRCA testing. Shares are Neutral rated.
April 2, 2014
16:21 EDTMYGNOn The Fly: Closing Wrap
Subscribe for More Information
10:35 EDTMYGNMyriad Genetics price target raised to $40 from $28 at Mizuho
Mizuho said the final CMS pricing for Myriad's BRCA testing represents a cut of about 20%, but that is still less severe than originally outlined. The firm raised its price target on Myriad Genetics to $40 following the ruling, but maintains its Neutral rating on the stock.
09:18 EDTMYGNOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTMYGNLeerink's life science tools analyst holds an analyst/industry conference call
Life Science Tools Analyst Leonard discusses the use of nextgen sequencing in a clinical context, early applications and uptake, the merits, demerits of various nextgen sequencing instruments and where new offerings fit on an Analyst/Industry conference call. Relevant companies ILMN, TMO, PACB, FLDM, MYGN, NSTG, GNMK, CPHD, LMNX and QGEN may be discussed on the Analyst/Industry conference call to be held on April 3 at 2 pm.
07:19 EDTMYGNMyriad Genetics price target raised to $44 from $42 at Cantor
Cantor increased its price target on Myriad Genetics after CMS raised prices for the company's BRCA 1&2 tests by about 52%, according to the firm. Cantor raised its estimates for Myriad Genetics and keeps a Buy rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use